Hunter Perkins Capital Management LLC Buys 10,664 Shares of Haemonetics Corporation $HAE

Hunter Perkins Capital Management LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 150.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 17,764 shares of the medical instruments supplier’s stock after purchasing an additional 10,664 shares during the period. Hunter Perkins Capital Management LLC’s holdings in Haemonetics were worth $866,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. Norges Bank bought a new stake in Haemonetics in the 2nd quarter worth $36,822,000. SG Capital Management LLC boosted its holdings in shares of Haemonetics by 92.5% during the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the period. AQR Capital Management LLC grew its stake in shares of Haemonetics by 157.9% in the second quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock worth $33,390,000 after purchasing an additional 275,683 shares during the last quarter. River Road Asset Management LLC increased its holdings in Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after purchasing an additional 260,624 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in Haemonetics during the 3rd quarter valued at approximately $8,557,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

Shares of HAE opened at $80.01 on Thursday. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The firm’s 50-day simple moving average is $70.27 and its two-hundred day simple moving average is $65.05. The stock has a market cap of $3.75 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business’s revenue was down 5.3% on a year-over-year basis. During the same period last year, the business earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HAE. BTIG Research restated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a report on Friday, November 21st. Robert W. Baird upped their price objective on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Barrington Research raised their target price on shares of Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.10.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.